Study Points

Prescription Opioids and Pain Management: The Tennessee Guidelines

Course #95131 - $15-

  • Back to Course Home
  • Participation Instructions
    • Review the course material online or in print.
    • Complete the course evaluation.
    • Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
  1. Inappropriate opioid analgesic prescribing for pain is defined as

    SCOPE OF THE PROBLEM

    Inappropriate prescription opioid analgesia takes several forms: failure to recognize an appropriate indication, inadequate dose titration, excessive opioid dosing, and continued prescription opioid use despite evidence that efficacy is lacking [1]. Appropriate opioid prescribing is essential to achieve pain control; to minimize patient risk of abuse, addiction, and fatal toxicity; and to minimize societal harms from diversion. The foundation of appropriate prescription opioid use encompasses a thorough patient assessment, treatment planning, and follow-up and monitoring. Essential for proper patient assessment and treatment planning is comprehension of the clinical concepts of opioid abuse and addiction, their behavioral manifestations in pain patients, and how these potentially problematic behavioral responses to opioids both resemble and differ from physical dependence and pseudo-dependence. Prescriber knowledge deficit has been identified as a key obstacle to appropriate opioid prescribing and, along with gaps in policy, treatment, attitudes, and research, contributes to widespread inadequate treatment of pain [2].

    Click to Review
  2. When initiating opioid treatment, all of the following are true, EXCEPT:

    CREATING A TREATMENT PLAN AND ASSESSMENT OF ADDICTION RISK

    The Tennessee Chronic Pain Guidelines enumerate several key principles to follow when initiating opioid therapy [94]. Practitioners should bear in mind that prior opioid therapy alone is not sufficient reason to continue opioids, and reasonable non-opioid treatments should be tried first. When prescription opioids are considered for women of childbearing age, providers should educate the patient about the risks of opioid use during pregnancy, including the risk of physical dependence and withdrawal in the newborn; upon initiation of opioid therapy, the provider should recommend reliable contraception. A urine drug test (UDT) should be performed before initiating any opioid or benzodiazepine during pregnancy [94]. A thorough clinical examination, including appropriate laboratory testing and other elements supporting the plan of care, should be documented in the medical record. Patients shall not be treated by the use of controlled substances through telemedicine.

    Before deciding to prescribe an opioid analgesic, clinicians should perform and document a detailed patient assessment that includes [1,94]:

    • History of the patient's pain condition and indications for opioid therapy

    • Nature and intensity of pain

    • Past and current pain treatments and patient response

    • Important comorbid conditions such as COPD, sleep apnea, diabetes, or congestive heart failure

    • Pain impact on physical and psychologic function

    • Social support, housing, and employment

    • Home environment (i.e., stressful or supportive)

    • Pain impact on sleep, mood, work, relationships, leisure, and substance use

    • Patient history of physical, emotional, or sexual abuse

    • The possibility of pregnancy, initially and on each subsequent visit

    The initial evaluation is intended to establish a current diagnosis that justifies the need for opioid medication. After this determination is made, it is important to assess the patient's risk for drug misuse and develop and document a treatment plan, including a discussion of treatment goals.

    Information obtained by patient history, physical examination, and interview, from family members, a spouse, or state Controlled Substance Monitoring Database (CSMD), and from the use of screening and assessment tools can help the clinician to stratify the patient according to level of risk for developing problematic opioid behavioral responses (Table 1). A UDT should be performed prior to initiating opioid treatment.

    Click to Review
  3. Before starting opioids for chronic pain, one should

    CREATING A TREATMENT PLAN AND ASSESSMENT OF ADDICTION RISK

    The initial evaluation is intended to establish a current diagnosis that justifies the need for opioid medication. After this determination is made, it is important to assess the patient's risk for drug misuse and develop and document a treatment plan, including a discussion of treatment goals.

    Click to Review
  4. A patient prescribed opioids for chronic pain who is 65 years of age and displays high levels of pain acceptance and active coping strategies is considered at what level of risk for developing problematic opioid behavioral responses?

    CREATING A TREATMENT PLAN AND ASSESSMENT OF ADDICTION RISK

    RISK STRATIFICATION FOR PATIENTS PRESCRIBED OPIOIDS

    Low Risk
    Definable physical pathology with objective signs and reliable symptoms
    Clinical correlation with diagnostic testing, including MRI, physical examination, and interventional diagnostic techniques
    With or without mild psychologic comorbidity
    With or without minor medical comorbidity
    No or well-defined and controlled personal or family history of alcoholism or substance abuse
    Age 45 years or older
    High levels of pain acceptance and active coping strategies
    High motivation and willingness to participate in multimodal therapy and attempting to function at normal levels
    Medium Risk
    Significant pain problems with objective signs and symptoms confirmed by radiologic evaluation, physical examination, or diagnostic interventions
    Moderate psychologic problems, well controlled by therapy
    Moderate coexisting medical disorders that are well controlled by medical therapy and are not affected by chronic opioid therapy (e.g., central sleep apnea)
    Develops mild tolerance but not hyperalgesia without physical dependence or addiction
    Past history of personal or family history of alcoholism or substance abuse
    Pain involving more than three regions of the body
    Defined pathology with moderate levels of pain acceptance and coping strategies
    Willing to participate in multimodal therapy, attempting to function in normal daily life
    High Risk
    Widespread pain without objective signs and symptoms
    Pain involving more than three regions of the body
    Aberrant drug-related behavior
    History of alcoholism or drug misuse, abuse, addiction, diversion, dependency, tolerance, or hyperalgesia
    Major psychologic disorders
    Age younger than 45 years
    HIV-related pain
    High levels of pain exacerbation and low levels of coping strategies
    Unwilling to participate in multimodal therapy, not functioning close to a near normal lifestyle
    HIV = human immunodeficiency syndrome, MRI = magnetic resonance imaging.
    Click to Review
  5. The Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R)

    CREATING A TREATMENT PLAN AND ASSESSMENT OF ADDICTION RISK

    The Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) is a 24-item, patient-administered questionnaire that assesses history of alcohol/substance use, psychologic status, mood, impulsivity, cravings, and stress. It uses a five-point rating scale for each response and classifies patients as low or high risk in relation to potential aberrant drug-related behaviors and the appropriate extent of monitoring [19].

    Click to Review
  6. For patients considered at medium risk for misuse of prescription opioids, urine drug testing should be completed every

    CREATING A TREATMENT PLAN AND ASSESSMENT OF ADDICTION RISK

    PATIENT RISK LEVEL AND FREQUENCY OF MONITORING

    Monitoring Tool Patient Risk Level
    Low Medium High
    Urine drug testEvery 1 to 2 yearsEvery 6 to 12 monthsEvery 3 to 6 months
    State prescription drug monitoring programTwice per yearThree times per yearFour times per year
    Click to Review
  7. In Tennessee, the disposal of unused or outdated prescription opioids, or other controlled medications, is best accomplished by

    CREATING A TREATMENT PLAN AND ASSESSMENT OF ADDICTION RISK

    The state of Tennessee has developed two types of disposal activities designed to control access and promote safe, convenient, and responsible disposal of prescription drugs [94]. The first is a system of permanent prescription drug collection boxes located within law enforcement agencies (in compliance with DEA regulations) where community members can safely deposit drugs in a secure manner. The goal is to establish at least one permanent prescription drug collection box in all 95 counties of the state. The second activity involves community one-day "take-back" events wherein the public is encouraged to discard unwanted and outdated medications including prescription drugs from their homes. These events serve to raise public awareness of the prescription drug epidemic and encourage the use of local permanent disposal sites available year-round. A map showing the locations of permanent drug collection boxes can be found online at https://tdeconline.tn.gov/rxtakeback.

    Click to Review
  8. The most common source of nonmedical use of prescribed opioids is from

    IDENTIFICATION OF DRUG DIVERSION/SEEKING BEHAVIORS

    Research has more closely defined the location of prescribed opioid diversion into illicit use in the supply chain from the manufacturer to the distributor, retailer, and the end user (the pain patient). This information carries with it substantial public policy and regulatory implications. The 2015 National Survey on Drug Use and Health asked non-medical users of prescription opioids how they obtained their most recently used drugs [51]. Among persons 12 years of age or older, 40.5% obtained their prescription opioids from a friend or relative for free, 34.0% got them through a prescription from one doctor (vs. 17.3% in 2009–2010), 9.4% bought them from a friend or relative, and 3.8% took them from a friend or relative without asking [51]. Less frequent sources included a drug dealer or other stranger (4.9%); multiple doctors (1.7%); and theft from a doctor's office, clinic, hospital, or pharmacy (0.7%) (vs. 0.2% in 2009–2010) [51].

    Click to Review
  9. Which of the following behaviors is the most suggestive of an emerging opioid use disorder?

    IDENTIFICATION OF DRUG DIVERSION/SEEKING BEHAVIORS

    In addition to aberrant urine screens, there are certain behaviors that are suggestive of an emerging opioid use disorder. The most suggestive behaviors are [48,54,55]:

    • Selling medications

    • Prescription forgery or alteration

    • Injecting medications meant for oral use

    • Obtaining medications from nonmedical sources

    • Resisting medication change despite worsening function or significant negative effects

    • Loss of control over alcohol use

    • Using illegal drugs or non-prescribed controlled substances

    • Recurrent episodes of:

      • Prescription loss or theft

      • Obtaining opioids from other providers in violation of a treatment agreement

      • Unsanctioned dose escalation

      • Running out of medication and requesting early refills

    Behaviors with a lower level of evidence for their association with opioid misuse include [48,54,55]:

    • Aggressive demands for more drug

    • Asking for specific medications

    • Stockpiling medications during times when pain is less severe

    • Using pain medications to treat other symptoms

    • Reluctance to decrease opioid dosing once stable

    • In the earlier stages of treatment:

      • Increasing medication dosing without provider permission

      • Obtaining prescriptions from sources other than the pain provider

      • Sharing or borrowing similar medications from friends/family

    Click to Review
  10. Which government agency is responsible for formulating federal standards for the handling of controlled substances?

    COMPLIANCE WITH STATE AND FEDERAL LAWS

    The DEA is responsible for formulating federal standards for the handling of controlled substances. In 2011, the DEA began requiring every state to implement electronic databases that track prescribing habits. Specific policies regarding controlled substances are administered at the state level [60].

    Click to Review

  • Back to Course Home
  • Participation Instructions
    • Review the course material online or in print.
    • Complete the course evaluation.
    • Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.